Skip to main content
Premium Trial:

Request an Annual Quote

Anthony Simonetta

Premium

Strategic Diagnostics announced late last week the resignation of CFO Anthony Simonetta, effective Jan. 5, to pursue other opportunities. The company is searching for a replacement. The company manufactures custom antibody products and analytical test kits for water, agricultural, industrial, environmental and scientific applications.


 
Note to Readers: This is the last issue of ProteoMonitor to publish in 2006. The next issue of the newsletter will appear on Thursday, Jan. 4.
The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.